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Abstract 19 
Pregnancy is a state of high metabolic demand. Fasting diverts metabolism to fatty acid oxidation, 20 
and the fasted response occurs much more rapidly in pregnant women than in the non-pregnant 21 
state. The product of the imprinted Delta-like homologue 1 gene (DLK1) is an endocrine signaling 22 
molecule that reaches a high concentration in the maternal circulation during late pregnancy. By 23 
utilising murine models with deleted Dlk1 we show that the fetus is the source of maternal 24 
circulating DLK1. In the absence of fetally-derived DLK1, the maternal fasting response is impaired. 25 
Furthermore, we found that maternal circulating DLK1 levels predict embryonic mass in mice and 26 
can differentiate healthy small for gestational age (SGA) from pathologically small infants in a human 27 
cohort. Therefore measurement of DLK1 in maternal blood may be a valuable method for diagnosing 28 
human disorders associated with impaired DLK1 expression, and to predict poor intrauterine growth 29 
and complications of pregnancy. 30 
Introduction 31 
Adaptations to maternal carbohydrate and lipid metabolism occur during pregnancy to ensure a 32 
continuous supply of nutrients to the fetus [1]. In late gestation fasting rapidly diverts maternal 33 
metabolism to fatty acid (FA) oxidation, and reductions in maternal plasma glucose and insulin 34 
combined with elevated FAs and ketones are seen in fasted pregnant women hours before these 35 
changes are observed in the non-pregnant state -a phenomenon known as ‘accelerated starvation’ 36 
[2].  37 
DLK1 is the product of an imprinted gene that is predominantly expressed from the paternally-38 
inherited chromosome during fetal development [3, 4]. It is a single-pass transmembrane protein 39 
that can be cleaved by extracellular proteases to give rise to a circulating form [5]. This soluble 40 
moiety reaches a high concentration in the maternal circulation during late pregnancy [6 - 8]. DLK1, 41 
also known as fetal antigen 1 (FA1) and pre-adipocyte factor 1 (PREF1), is known to play a crucial 42 
role in adipose homeostasis [9]. Our previous studies with genetically-modified mice showed that 43 
DLK1 shifts nutrient metabolism towards FA oxidation, both in the context of the transition from 44 
birth to weaning [10], and following high-fat feeding, in part through modulation of the growth 45 
hormone axis [11]. Since pregnancy is similarly associated with global shifts in nutrient partitioning, 46 
we hypothesised that high DLK1 levels during this period might modulate maternal metabolic 47 
adaptations. 48 
Here we show that the fetus is the source of maternal circulating DLK1 during pregnancy. In the 49 
absence of fetally-derived DLK1, maternal ketone levels are not elevated during fasting, suggesting 50 
that DLK1 is part of the accelerated starvation response. Furthermore, lack of DLK1 during the 51 
mother’s development additionally impairs her ability to respond to the metabolic demands of 52 
pregnancy. We demonstrate that circulating DLK1 levels are positively associated with embryonic 53 
mass in mouse pregnancies and that DLK1 levels are significantly lower in pregnant women who go 54 
on to deliver a small for gestational age (SGA) infant. SGA is simply a descriptive term for an infant 55 
whose birth weight falls below a statistical threshold, but is of clinical interest because a proportion 56 
of these infants are small because of fetal growth restriction (FGR) [12]. We found that there is no 57 
significant difference in DLK1 levels between healthy SGA and controls, but there is a highly 58 
statistically significant reduction in DLK1 in FGR. These data support our findings in the mouse that 59 
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reducing DLK1 dosage compromises pregnancy. Moreover, measuring DLK1 has considerable 60 
potential utility in the clinic to identify pregnancies that will require additional monitoring and 61 
obstetrical intervention. 62 
 63 
Results  64 
Maternal circulating DLK1 is derived from the conceptus 65 
To determine the source and function of high maternal DLK1 in pregnancy we utilised genetically 66 
modified mice that lack a functional copy of Dlk1 [13]. We first explored the effect of loss of a 67 
functional Dlk1 gene in breeding-age females. Total body mass did not vary between genotypes 68 
(wild-type (WT), Null (Dlkm-/p-) and Mat (maternal heterozygotes, Dlk1m-/p+), Supplementary Fig. 1a) 69 
but body composition was markedly different. At 12 weeks, virgin Null females had increased 70 
abdominal white adipose tissue (WAT), and reduced muscle mass compared to Dlk1-expressing 71 
females (Supplementary Fig. 1b, 1c). These alterations in body composition are likely to be due to 72 
loss of Dlk1 during embryogenesis, since Dlk1 Null embryos had reduced size due to a reduction in 73 
skeletal length and lean mass from at least as early as E18.5 (Supplementary Fig. 1d-f). These 74 
animals caught up in weight in the preweaning period, but body composition was not normalised 75 
(Supplementary Fig. 1g, 1b-c). Elevated WAT mass at 12 weeks was accompanied by an increase in 76 
serum leptin levels (Supplementary Fig. 1h). In humans high BMI is associated with elevated DLK1 77 
[14], suggesting that levels of this protein might be modulated by nutritional status. 78 
Next, we compared DLK1 in plasma from virgin WT females, with levels at 15 days post conception 79 
(E15.5) in WT females that had been mated to WT males. Plasma DLK1 levels increased 80 
approximately 5-fold during the first 2 weeks of mouse pregnancy (Fig. 1a). As Dlk1 is expressed 81 
predominantly from the paternally-inherited chromosome [3, 4], a cross between a Null mother and 82 
a WT father produces offspring that express Dlk1 at WT levels, since they all inherit an intact Dlk1 83 
gene from their father (they are maternal heterozygotes for the deleted allele (Dlk1m-/p+, Mats)). 84 
Conversely, a cross between a Dlk1-expressing mother (either a Mat or WT) and a Null father 85 
produces offspring that that do not express Dlk1 (they are, respectively, homozygotes or paternal 86 
heterozygotes for the deleted allele (Dlk1m-/p- or Dlk1m+/p-, Nulls or Pats)) since maternally inherited 87 
Dlk1 is repressed by imprinting. All crosses are summarised in Fig. 1b. In pregnancies where both the 88 
mother and the conceptus had inherited the ablated Dlk1 gene (Null x Null), DLK1 could not be 89 
detected in the maternal plasma (Fig. 1a and 1c), confirming that there was no residual DLK1 90 
produced from the ablated Dlk1 allele.  91 
We conducted serial measurements of maternal plasma DLK1 in crosses of mice where the mother, 92 
the conceptus, or both were unable to express Dlk1 (Fig. 1b, 1c). DLK1 was detected at high levels in 93 
maternal plasma only if the conceptus retained the ability to express Dlk1 (Fig. 1c). Thus, the 94 
conceptus is the source of elevated maternal plasma DLK1 in pregnancy. DLK1 levels in maternal 95 
plasma began to rise between E9.5 and E11.5 in all crosses that contained Dlk1-expressing 96 
conceptuses (Fig. 1c). This rise coincides with the time of formation of the definitive placenta in the 97 
mouse [15].  98 
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Unexpectedly, Null females crossed with WT males had equal or higher levels of plasma DLK1 99 
compared with WT or Mat females crossed to WT males (Fig. 1d). Since DLK1 levels are known to 100 
correlate with the number of conceptuses in the litter [6], we investigated whether litter size was 101 
affected by maternal genotype. Consistently, Null mothers had larger litters than mothers with a 102 
functional copy of Dlk1 (Fig. 1e and Supplementary Table 1). This was not due to a sampling error 103 
caused by controlling our cohort to exclude extremes of litter size and genotype ratio, as when we 104 
pooled the data for all crosses generated, Null females consistently produced approximately one 105 
additional conceptus compared with WT or Mat females (WT and Mat mean litter size = 7.0 ± 0.3, n 106 
= 40 litters; Null mean litter size 8.2 ± 0.3, n = 48 litters, p < 0.001, Mann Whitney test). Appropriate 107 
maternal leptin levels are necessary for conception and survival of the early embryo [16]; leptin 108 
increases the invasiveness of the early embryo[17] and enhances ovulation[18]. Our finding that Null 109 
females had increased fecundity is consistent with their elevated leptin levels (Supplementary Fig. 110 
1h). 111 
When the amount of maternal plasma DLK1 per expressing conceptus was calculated, those in the 112 
Null x WT cross produced a similar amount of DLK1 to conceptuses in WT x WT or Mat x WT crosses 113 
(Fig. 1e and Supplementary Table 1). However, litters where only half of the conceptuses had an 114 
intact Dlk1 allele (Null x Mat cross, Fig. 1b) produced significantly more DLK1 per conceptus than 115 
litters where all were able to express Dlk1 (Fig. 1f).  116 
Fetal, not placental, origin of maternal circulating DLK1 117 
To distinguish whether the placenta or the embryo is the source of maternal plasma DLK1, we 118 
utilised additional models of Dlk1 dosage manipulation. We have previously described a transgenic 119 
line that recapitulates Dlk1 expression in the embryo, but not in the placenta [19] (Fig. 2a). We 120 
crossed the transgene onto a Dlk1-/- background (Null–TG) and measured transgene-specific Dlk1 121 
expression in the embryo and placenta (Fig. 2b, c). As expected, DLK1 expression in the embryo 122 
closely resembled the WT, but DLK1 was lost from the fetal endothelial compartment of the Null–TG 123 
placenta. However, DLK1 expression was retained in a small population of cells in the placental 124 
labyrinth; these cells had large nuclei, consistent with a trophoblast identity, and contributed 24% of 125 
the WT Dlk1 expression (Fig. 2d). The placenta is a potential source of circulating DLK1 since, like the 126 
embryo, it expresses cleavable isoforms Dlk1A and B. As previously reported, the transgene 127 
recapitulated the isoform-specific Dlk1 expression [11] (Fig2e). We crossed Null–TG fathers to Null 128 
mothers to generate litters where all Dlk1 was transgene-derived (Supplementary Fig. 2). We found 129 
that maternal circulating DLK1 levels were not different from WT x WT crosses (Fig. 2f, 130 
Supplementary Table 1), indicating that DLK1 originates from either the embryo or a trophoblast 131 
population of the placenta. 132 
We used a conditional allele of Dlk1 [20] to ablate expression in all of the cells of the embryo and the 133 
fetal endothelium of the placenta, using the Meox2Cre[21] (Fig. 2g). DLK1 was largely absent in the 134 
embryo when the conditional allele (Dlk1fl/fl) was crossed to the Meox2Cre (Fig. 2h). Confirmation 135 
that the Meox2Cre was active in the fetal endothelium of the placenta was achieved by crossing to a 136 
mTmG reporter line [22] (Fig. 2i). As predicted, DLK1 expression in the placenta was absent from the 137 
fetal endothelial compartment in the conditional knock-out line (Fig 2i). In the embryo and placenta 138 
residual Dlk1 expression was 14–17% of WT levels following conditional targeting (Fig 2j, k). We 139 
crossed Meox2Cre+/- mothers to either WT or Dlk1fl/fl fathers to generate litters where Dlk1 was 140 
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undeleted or deleted in half of the litter (Supplementary Fig. 2 – since the Meox2Cre is lethal in the 141 
homozygous state we were unable to generate a fully deleted litter). We found that maternal 142 
circulating DLK1 levels in Dlk1–deleted litters were approximately 50% of those where DLK1 was not 143 
deleted (Fig. 2l and Supplementary Table 1), indicating that maternal circulating DLK1 does not 144 
originate from the trophoblast cells of the placenta. Taken together these data show that the source 145 
of maternal circulating DLK1 is the embryo, not the placenta. 146 
Pregnancies lacking DLK1 have compromised lipid metabolism 147 
We next investigated whether Dlk1 expression dosage was relevant to the metabolic adaptations of 148 
pregnancy. Our experimental design allowed us to assess the contribution of both maternal Dlk1 149 
genotype, and the presence or absence of circulating DLK1 from the conceptus (Fig. 1b). During 150 
pregnancy, total body weight and food intake did not significantly differ between the groups 151 
(Supplementary Table 2) despite the larger litters in Null females (Fig. 1e, Supplementary Table 1). 152 
When weight gain was normalised for number of conceptuses in the litter or total litter mass, Null 153 
females gained relatively less weight over the course of pregnancy (Fig. 3a, b). WAT, brown adipose 154 
tissue (BAT) and liver mass increased during pregnancy (Supplementary Table 3). Virgin and 155 
pregnant Null females had enlarged abdominal WAT deposits compared to WT and Mat 156 
(Supplementary Table 3), but consistent with their reduced overall weight gain, Null females gained 157 
less WAT during pregnancy compared with Dlk1–expressing females (Fig. 3c). This gain was depot–158 
specific, since the Null females had a similar retroperitoneal WAT mass to Mat and WT females when 159 
virgins and when pregnant at E15.5. As in virgins, muscle mass was reduced in the pregnant Null 160 
females, and brain mass did not differ between the groups (Supplementary Table 3). In summary, 161 
females lacking Dlk1 during their own development had altered body composition as virgins, and 162 
gained less adipose tissue during pregnancy, suggesting that maternal loss of Dlk1 function limits 163 
adipose plasticity during pregnancy. Conceptus–derived circulating DLK1 did not modify any of these 164 
body composition parameters (Supplementary Tables 2 and 3). 165 
In contrast, circulating DLK1 did modify levels of circulating maternal metabolites. While Null x WT 166 
responded to pregnancy with a reduction in total cholesterol and HDL–C, pregnant Null females 167 
lacking conceptus-derived DLK1 (Null x Null) had a much less marked reduction in HDL–C 168 
(Supplementary Table 4). In addition, while Mat females with a normal pregnancy–induced rise in 169 
DLK1 had elevated levels of circulating ketones, Mat females without pregnancy-associated DLK1 did 170 
not. These changes occurred without alterations to circulating insulin levels (Supplementary Table 171 
4) in free–fed females.  172 
Upon fasting, Null females without pregnancy–induced DLK1 production failed to elevate their 173 
circulating ketones and were relatively hyperglycaemic, suggesting that the switch from glucose to 174 
fatty–acid fuel utilisation had not occurred (Fig. 3d, e), despite normal insulin levels (Fig. 3f). This 175 
was supported by the finding that Null mothers with circulating DLK1 had elevated hepatic 176 
expression of Hmgcs2 (encoding a rate limiting enzyme in the ketogenesis pathway, Fig. 3g) 177 
compared to Null mothers without circulating DLK1. As in non–fasted animals, Null mothers without 178 
conceptus–derived DLK1 did not experience the same magnitude of decrease in circulating HDL–C 179 
compared to Null females with circulating DLK1 (Fig. 3h, i). Combined, these data suggest that failure 180 
to elevate DLK1 during pregnancy prevents normal maternal metabolic adaptations – specifically 181 
reduced HDL–C and an accelerated response to starvation by the induction of ketogenesis.  182 
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We previously reported that non–pregnant transgenic mice with DLK1 levels elevated to a similar 183 
level as those during pregnancy (DLK1 levels in Dlk1-transgenic females at 6 months 343 ± 37ng/mL  184 
compared to WT (x WT) females at 12 weeks, E15.5, 223 ± 24ng/mL) have reduced circulating 185 
cholesterol levels and increased peripheral FA utilisation, in part due to increased growth hormone 186 
(GH) production [11]. GH levels are elevated in pregnancy in both humans and rodents (although the 187 
source of rodent GH in pregnancy is not clear [23], as they lack the placental GH gene variant found 188 
in primates [24]). Since GH-like molecules promote maternal adaptations to pregnancy [24], we 189 
asked if circulating GH was affected by Dlk1 during gestation. GH levels were elevated 13–fold by 190 
E15.5 of pregnancy in WT mice, but pregnancies entirely lacking Dlk1 had much less marked 191 
elevation in GH levels (approximately 3–fold in the Null x Null cross, Fig. 3j). These changes occurred 192 
in the absence of alterations to endocrine regulators of GH; estradiol and corticosterone (Fig. 3k, l), 193 
and pituitary Gh mRNA levels were unaffected (Supplementary Fig. 3). We concluded that 194 
pregnancies without a conceptus–derived rise in maternal plasma DLK1 have altered fuel 195 
metabolism, which may in part be due to impaired GH release. 196 
Maternal circulating DLK1 reports fetal outcome 197 
We compared embryo and placental weights of conceptuses with similar genotype in different 198 
maternal and litter contexts (Fig. 1b, Supplementary Table 5). Null embryos and placentae were 199 
smaller than WT or Mats, and neither the maternal genotype (and associated litter size) nor the 200 
presence/absence of circulating DLK1 affected weight at this stage (E15.5, Supplementary Table 5). 201 
However, Mat embryos in mixed litters with Null littermates (Null x Mat crosses) were significantly 202 
larger than Mat or WT embryos in any other context. Interestingly, since this group of conceptuses 203 
generated a greater amount of DLK1 per conceptus (Fig. 1e), this demonstrates a direct link between 204 
embryonic size and maternal circulating DLK1 levels. Placental size was not similarly increased at this 205 
gestational stage (Supplementary Table 5).  206 
We therefore sought to determine whether there was any relationship between maternal plasma 207 
DLK1 levels and fetal growth in pregnant women. We used data and samples from a previously 208 
described prospective cohort, the Pregnancy Outcome Prediction study [25, 26]. A total of 4,512 209 
women having first pregnancies were recruited and outcome data were available from 4,200. We 210 
studied a sample of 45 women who delivered a baby with a customized birth weight percentile less 211 
than the 5th (SGA) at term and had a plasma sample available which had been obtained around 36 212 
weeks of gestational age (wkGA). We then identified two comparison groups: (1) matched controls 213 
(available for 43 out of the 45 cases), (2) a random sample from the cohort. In the former 214 
comparison group, women were one–to–one matched on the basis of maternal age, body mass 215 
index, smoking, fetal sex and mode of delivery to controls delivering a normally grown infant, i.e. 216 
samples were analysed as a matched case control study [27]. The maternal and outcome 217 
characteristics of these three groups are tabulated (Supplementary Table 6). Analysis of the 218 
matched cases and controls indicates no significant differences between the groups in either the 219 
matching characteristics or the gestational age of measurement of DLK1 (Supplementary Table 7). 220 
However, compared with the matched controls, the birth weights of their infants were 820 g lower 221 
on average. 222 
Different phenotypes of SGA were classified according to research ultrasonographic examination, 223 
and the details of this are described elsewhere [26]. Ultrasonic assessment included serial Doppler 224 
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flow velocimetry of the uterine and umbilical arteries. Both women and clinicians were blinded to 225 
the results of these research scans. High resistance uterine artery flow was defined as a mean 226 
pulsatility index in the top decile at 20 wkGA, high resistance umbilical artery flow was defined as a 227 
pulsatility index in the top decile at 36 wkGA, and low abdominal circumference growth velocity was 228 
defined as a difference in abdominal circumference z score between the 36 and 20 wkGA scans 229 
falling in the lowest decile (i.e. this group includes the fetuses which showed the greatest reduction 230 
in the relative size of the abdominal circumference at the time of the 36 wkGA scan). Among the 43 231 
SGA pregnancies with matched controls, 20 (47%) had none of these features and were called 232 
healthy SGA and 23 (53%) had one or more of these features and were defined as FGR (birth 233 
outcomes of these 2 groups are presented in Supplementary Table 8). 234 
DLK1 levels were measured in maternal plasma obtained at a mean of 36 weeks and 1 day of 235 
gestational age (SD 2.7 days), (Fig. 4a). When compared with matched controls (Supplementary 236 
Table 9), DLK1 was lower overall in women with SGA infants (mean difference = –9.44, P=0.0001). 237 
However, when this population was divided into healthy SGA and FGR, there was no significant 238 
difference between healthy SGA and controls (mean difference –4.97, P=0.22), but there was a 239 
highly statistically significant reduction in DLK1 in FGR (mean difference = –13.33, P<0.0001). When 240 
analyzed by the different phenotypes of FGR, there were very strong associations between DLK1 241 
concentration and SGA in the presence of either high resistance umbilical artery Doppler (mean 242 
difference = –17.13, P<0.0001) or low abdominal circumference growth velocity (mean difference = 243 
–11.96, P=0.007). 244 
The strength of the association was then further evaluated by comparing cases with the random 245 
sample of the cohort using Receiver Operating Characteristic (ROC) curve analysis (Fig. 4b). Overall, 246 
DLK1 was moderately predictive of SGA: area under the ROC curve (AUROCC) 0.65 (95% CI 0.54 to 247 
0.77, P=0.01). Similarly to the comparison with matched controls, there was no significant 248 
association between DLK1 levels and healthy SGA (AUROCC=0.59; 95% CI=0.44 to 0.74; P=0.22), but 249 
there was a highly statistically significant association with FGR (AUROCC=0.71; 95% CI=0.58 to 0.84; 250 
P=0.001). Again, the strongest association was with SGA combined with high resistance umbilical 251 
artery Doppler (AUROCC=0.82; 95% CI=0.70 to 0.93; P<0.0001).  252 
Discussion 253 
During late pregnancy the mother must be able to adapt her metabolism to changes in food 254 
availability in order to maintain a constant supply of energy to the fetus. Here we have shown in the 255 
mouse that both DLK1 expression in maternal tissues, and circulating DLK1 derived from the fetus 256 
are necessary for appropriate metabolic adaptations to pregnancy; specifically to provide metabolic 257 
plasticity by allowing the switch to FA utilisation when resources are limited during fasting.  258 
Moreover, since it is derived from the fetus, maternal circulating DLK1 levels provide a non–invasive 259 
read–out of embryonic state. Our data indicate that maternal plasma DLK1 levels are lower in 260 
pregnancies complicated by FGR, and suggest that DLK1 measurements in women may be clinically 261 
useful to differentiate healthy SGA infants from those which are pathologically small, an area of 262 
intense clinical interest. Interestingly, lower DLK1 levels were most strongly associated with high 263 
resistance patterns of flow in the umbilical artery and slow abdominal circumference growth 264 
velocity. The potential clinical significance of clinical measurement of DLK1 is underlined by the fact 265 
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that we have previously reported that these two measures were the most effective predictors of 266 
neonatal morbidity in pregnancies where the baby was suspected to be small on the basis of 267 
ultrasonic fetal biometry [26]. Previous studies have reported contradictory associations between 268 
cord blood DLK1 levels and birth weight [28], as well as in complications of pregnancy [29]. Those 269 
studies used a commercial ELISA which reports DLK1 levels that were ~100x lower than values 270 
reported in both the original pioneering work on DLK1 as a soluble factor in pregnancy [7] and the 271 
values measured in this study. This suggests that further assay development may be required before 272 
DLK1 is a suitable biomarker for clinical use. However, our data is consistent with a recent study that 273 
reported a genomic variant at the imprinted DLK1–GTL2 locus in humans that segregates with 274 
birthweight [30], and with a study where elevated DLK1 expression was associated with LGA 275 
pregnancies [31].  276 
The analysis of human plasma samples focused on blood samples obtained at 36 wkGA. The 277 
gestational age of analysis was purposeful, as at this stage of pregnancy delivery is a safe and 278 
effective intervention to mitigate the risks of FGR where it is clinically suspected. We have previously 279 
outlined a case for screening women for adverse pregnancy outcome in late gestation [32]; around 280 
one third of all intrauterine fetal deaths (IUFDs) occur at or after 37 weeks and about 30% of all 281 
IUFDs at term are thought to be related to poor fetal growth [12]. However, detection of FGR at 282 
earlier gestational ages would also be valuable, and further work could address whether these 283 
associations are present at earlier gestational ages, and whether DLK1 is also predictive of other 284 
adverse pregnancy outcomes.  285 
In conclusion our findings highlight DLK1 measurement as a valuable prenatal diagnostic for known 286 
disorders of impaired fetal DLK1 production (such as Temple syndrome [33]), and indicate that 287 
measuring maternal plasma DLK1 may have more general utility to differentiate healthy SGA from 288 
pathological complications of pregnancy requiring obstetric intervention.   289 
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 385 
Figure legends 386 
Figure 1. The conceptus is the source of elevated maternal plasma DLK1 in late gestation. 387 
(a) Maternal plasma DLK1 levels are elevated during pregnancy. Serum DLK1 levels in non-pregnant 388 
WT females (WT NP, n = 8), pregnant WT females crossed to WT males at E15.5 gestation (WT x WT, 389 
n = 10), and pregnant Dlk1-/- females crossed to Dlk1-/- males at E15.5 (Null x Null, n = 4). (b) 390 
Summary of experimental crosses used in the study. (c) Serial plasma DLK1 measurements over the 391 
course of pregnancy (n = 4 females/time–point/group). Groups differ significantly by cross, time–392 
point and the interaction between them (each p < 0.001 by Two-way ANOVA). Dotted line 393 
represents the detection threshold of the ELISA. (d) Maternal plasma DLK1 at E15.5 (n = 7–8 394 
females/group). Groups differ significantly by cross and DLK1 levels rise only when the conceptus 395 
has a functional copy of Dlk1. nd = not detected (below assay threshold). (Inset) DLK1 in maternal 396 
plasma at E15.5 normalised to number of Dlk1–expressing embryos in the litter (n = 8 litters/group). 397 
Mat embryos in the Null x Mat cross generate significantly more DLK1 than those in other 398 
experimental crosses. (e) Litters from Null mothers have more embryos than litters from WT or Mat 399 
mothers. Litter size by maternal genotype in WT (n = 8), Null (n = 24) and Mat (n = 16) mothers. 400 
Vertical bars show mean ± s. e. m. Groups were compared by Kruskall-Wallis test, with Dunn’s 401 
Multiple comparison post-hoc test as indicated (a, d, e), *p < 0.05, **p < 0.01, ***p < 0.001. 402 
Figure 2. Fetus not placenta is the source of maternal circulating DLK1. 403 
(a) Schematic of Dlk1 expression in Null-TG conceptuses. (b) DLK1 expression (brown staining) the 404 
WT, Null and Null–TG embryo. Scale bar 2mm. (c) DLK1 is not detected in the fetal endothelium of 405 
the Null-TG placenta but is retained in cells with large nuclei. Scale bars left 500um, right 50um. (d) 406 
Dlk1 expression in the Null-TG, WT levels, and Null placentae (n = 7–8 per group) *** p < 0.001 by 407 
Dunnett’s Multiple comparison post-test (vs WT) following One-Way ANOVA. (e) Expression of 408 
cleavable (Dlk1A/B) and membrane-bound isoforms (Dlk1C/D) of Dlk1 in WT and Null-TG placentae. 409 
(f) DLK1 levels in maternal plasma in Null x Null-TG litters (n = 7–8 females/cross). (g) Schematic of 410 
Dlk1 expression in Meox2Cre/Dlk1fl/fl conceptuses. (h) DLK1 expression in the Meox2Cre/Dlk1fl/fl 411 
embryo compared to a Meox2Cre/Dlk1+/+ control. Scale bar 2mm. (i–top) Meox2Cre crossed to the 412 
mTmG reporter results in GFP+ cells following Cre excision, and mTomato+ in non–recombined cells. 413 
(i–bottom) Dlk1 is not detected the fetal endothelium of the Meox2Cre/Dlk1fl/fl placenta but some 414 
labyrinthine expression of DLK1 is retained. Scale bars left 500um, right 50um. (j) and (k) Dlk1 415 
expression in the WT, Meox2Cre/Dlk1+/+ and Meox2Cre/Dlk1fl/fl embryo and placenta (5–8 per 416 
group), **p < 0.01, ***p < 0.001 as in (d). (l) Maternal plasma DLK1 in Meox2Cre+/- females crossed 417 
with Dlk1+/+ (control) or Dlk1fl/fl males (n = 6 females/cross), *p < 0.05 compared by Students’ t–test. 418 
All measurements performed at E15.5. Vertical bars show mean ± s. e. m. 419 
Figure 3. Maternal genotype and conceptus-derived DLK1 alters maternal metabolism. 420 
Female weight at E15.5 minus weight on the day of conception (E0.5), divided by the number of live 421 
fetuses (a), or total litter mass (sum of all placental and embryonic masses within the litter), (b). Null 422 
females gain significantly less weight. (c) Derived abdominal WAT gain during pregnancy –pregnant 423 
WAT weight for each cross minus average non–pregnant WAT weight for each genotype, expressed 424 
as % WT weight gain. Null females ‘gain’ significantly less abdominal WAT. Fasted 3-425 
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hydroxybutyrate, 3-OH (d), glucose (e), insulin (f), total cholesterol (h) and HDL-cholesterol (i) in 426 
maternal plasma from Null females crossed to WT or Null males, at E15.5. (g) Relative expression of 427 
Hmgcs2 in maternal liver at E15.5, in Null females crossed to WT or Null males, Growth Hormone 428 
(GH, j), Estradiol (E2, k) and Corticosterone (l) levels in all groups. Vertical bars show mean ± s. e. m 429 
(n = 6–8 females per group). Comparisons (a-c, and j-l) were compared by One-way ANOVA, with 430 
Bonferroni's Multiple comparison post-hoc test as indicated, *p < 0.05, **p < 0.01. Pregnant and NP 431 
GH and corticosterone samples did not have equal variance, so only pregnant samples were 432 
compared. WT NP vs WT x WT were compared to each other using a Student’s t-test with Welch’s 433 
correction, ***p < 0.001. (d-i) were compared by Student’s t-test; *p < 0.05, **p < 0.01, ***p < 434 
0.001. 435 
Figure 4. Low DLK1 in human pregnancy is associated with pathological SGA. 436 
(a) Scatter plot of differences in DLK1 levels in maternal plasma of 43 pairs of matched pregnant 437 
women, differing by SGA outcome. Pathological = any of the fetal growth restriction (FGR) indicators 438 
(UTPI 20wk decile 10, n = 8 pairs; UMPI 36wk decile 10, n = 10 pairs; ACGV 20-36wk decile 1, n = 12 439 
pairs). The short horizontal lines represent means of the differences. (b) Receiver Operating 440 
Characteristic (ROC) curve analysis showing the strength of association of maternal plasma DLK1 and 441 
SGA comparing cases (n = 45) with the random sample of the cohort (n = 41). AUC = area under 442 
curve, 95% confidence interval (CI) and p values for testing the null hypothesis (AUC = 0.5) are 443 
shown on respective graphs. 444 
  445 
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Methods 446 
Animal work 447 
Mice.  448 
All animal work was carried out in accordance with UK Government Home Office licencing 449 
procedures. Mice were housed in a temperature and humidity controlled room (21 °C, 55 % 450 
humidity) with a 12 hour / 12 hour light-dark cycle. All mice were fed standard RM3 (E) diet (Special 451 
Diets Services) ad libitum, given fresh tap water daily and re-housed in clean cages weekly. Mice 452 
were weaned at 21 days postnatum, or a few days later if particularly small. Thereafter, they were 453 
housed in single-sex groups (5 per cage maximum) or occasionally singly housed, except when 454 
breeding. 455 
The Dlk1 knock-out line (Dlk1tm1Srba) results in the replacement of 3.8 kb of the endogenous Dlk1 456 
allele, including the Dlk1 promoter and its first three exons, with a neomycin resistance cassette 457 
[13]. The Dlk1 knock-out line was backcrossed onto the C57BL6/J background for at least 10 458 
generations, and then routinely maintained by homozygous crosses (Dlk1 tm1Srba / tm1Srba x Dlk1 tm1Srba / 459 
tm1Srba ). For experimental purposes, maternal heterozygotes (Dlk1 tm1Srba /+, Mats) and wild-types 460 
(Dlk1+/+, WTs) were generated. In all cases experimental WT mothers were the age-matched 461 
littermates of Mat females, both arising from an intercross between a Mat female and a stock 462 
C57BL6/J male.  463 
Conditional Dlk1 deletion (Dlk1tm1.1Jvs) mice on a C57BL6/J background were obtained from JAX, 464 
backcrossed to generate homozygotes, and genotyped as described previously [20]. Meox2Cre 465 
heterozygous (Meox2tm1(Cre)Sor/+) females on a C57BL6/J background were maintained as 466 
heterozygotes as described[21]. Conditional mutants were generated by crossing Meox2Cre+/- 467 
females to Dlk1fl/fl males, and the recombination event was detected by PCR as described previously 468 
[20]. Meox2Cre-induced recombination in the fetal endothelium of the placenta was validated by 469 
crossing to the mTmG dual reporter line (Gt(ROSA)26Sortm4(ACTB-tdTomato, -EGFP)Luo/J), obtained from JAX 470 
and genotyped as described previously [22]. These mice ubiquitously express a red fluorescent 471 
protein, except following recombination by Cre, which causes GFP to be expressed instead. 472 
Experimental cohort.  473 
At eight weeks postnatum, female mice were weighed and excluded from the study if <15g. The 474 
blood glucose level was measured in study females and a 20-30 μl blood sample was taken from the 475 
tail vein for plasma extraction. Female mice were then mated with stud males in the crosses 476 
described in Fig 1b. Females were monitored once daily between 08:00 and 10:00 for the presence 477 
of a vaginal plug. The day of plug discovery was designated embryonic day 0.5 (E0.5). Additional 478 
eight-week-old female WT, Mat and Null mice were not mated, but remained in their home cage 479 
until the experimental start day (E0.5-equivalent). Blood sampling was repeated on E0.5, E7.5, E9.5, 480 
E11.5, E13.5 and E15.5, between 10:45 and 12:30. From E0.5, the female mice were singly housed 481 
and provided with a non-limiting, weighed quantity of standard RM3 (E) diet. The remaining food 482 
weight was recorded at E7.5 and E15.5 as an indicator of food intake. On E15.5, the female mice 483 
were killed by terminal anaesthesia using ~0.8 mg pentobarbitol (Dolethal; Vetoquinol) per gram 484 
body weight, injected intra-abdominally. Upon cessation of the twitch reflex, mice were 485 
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exsanguinated by cardiac puncture. Maternal and conceptus tissues were weighed and collected for 486 
processing. All dissections were carried out between 12:00 and 17:00. The following exclusion 487 
criteria were applied to all mice: (1) if the female mouse did not show evidence of a vaginal plug 488 
after 11 days spent with a stud male; (2) if a pregnant mouse carried <5 or >12 live conceptuses at 489 
E15.5; (3) if a pregnant mouse with a mixed-genotype litter had an unbalanced conceptus genotype 490 
ratio (>3:<1 genotype ratios, when the predicted Mendelian ratio was 1:1); (3) if upon dissection the 491 
female mouse was found to have a confounding anatomical abnormality; (4) if the female mouse 492 
died during the experiment. 493 
Fasted cohort.  494 
On E15.5, the female mice were fasted for 4 hours then their tail blood glucose was measured. They 495 
were immediately killed by terminal anaesthesia and exsanguinated as above. All fasts were started 496 
between 09:15 and 11:00 and all dissections were carried out between 13:15 and 16:00. 497 
Null-TG mice were generated by crossing Dlk1 70kb BAC transgenic mice (TgDlk1-70C) on a C57BL6/J 498 
background with the Dlk1tm1Srba knock-out line, and genotyped as described above and as previously 499 
described [19].  500 
 501 
Immunohistochemistry.  502 
Immunostaining was carried out on wax-embedded material as described previously [19], using an 503 
anti-DLK1 antibody(R&D AF8277). 504 
Serum and tissue biochemistry.  505 
Enzymatic assay kits were used for determination of plasma FFAs (Roche), TAGs and glycerol (Sigma-506 
Aldrich), and Cholesterol (Dade-Behring). ELISA kits were used for measurements of Insulin 507 
(Crystalchem), Estradiol (Calbiotech), Leptin and Growth Hormone (Millipore), all according to 508 
manufacturers’ instructions.  Blood glucose levels were measured using a glucose meter (One Touch 509 
Ultra, LifeSpan, UK). The methods for the mouse DLK1 ELISA and tissue determination of TAG were 510 
described previously [10]. The human DLK1 ELISA was used for measurement on maternal plasma 511 
according to the manufacturers’ instructions (Adipogen). 512 
Real-time quantitative PCR. 513 
mRNAs were analysed by RT-PCR as described [10]. Quantification was performed using the relative 514 
standard curve method, and target gene expression was normalised to the expression of a reporter 515 
gene (mean of Hprt and α tubulin for liver samples, β actin for pituitary samples, and mean of all 3 516 
for e15.5 placenta and embryo samples), the expression of which did not differ between the groups. 517 
All primers (sequences in Supplementary Table 10) amplified with efficiency greater than or equal to 518 
85%. 519 
Statistical analysis of animal data.  520 
All statistical tests were performed using the GraphPad Prism Software version 4.00 for Windows, 521 
GraphPad Software, San Diego California USA. Data was tested for Normal distribution (Kolmogorov-522 
Smirnov test) and statistical evaluation applied accordingly. Tests, significance values and number of 523 
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samples analysed are indicated in the respective figure/table legends, and all error bars represent 524 
the standard error of the mean (s.e.m). 525 
Human data 526 
Study design and participants. 527 
All samples and data were obtained from the Pregnancy Outcome Prediction (POP) study as 528 
described previously[25, 26]. Ethical approval for the study was obtained from the Cambridgeshire 529 
Research Ethics Committee (reference 07/H0308/163). Participants provided written consent. The 530 
plasma had been frozen on the day of collection and stored at -80°C. Measurement of DLK1 was 531 
performed blind to both the ultrasonic and outcome data.  532 
Maternal characteristics of the SGA infants included in this analysis were representative of the whole 533 
POP study population (Supplementary Table 11). Since the analysis required a 36 week sample, all 534 
SGA infants included were born at term whereas 15% of the SGA cases not included in the analysis 535 
were born preterm. Therefore, the SGA infants not included in the analysis weighed less at birth. 536 
However, the distribution of the birth weight percentile was not markedly different between the 537 
groups. The distribution of DLK1 concentration was fairly normal in cases and unmatched controls, 538 
and also the difference in DLK1 concentration between cases and matched controls was normally 539 
distributed.  540 
Analysis. 541 
The association between DLK1 and SGA was assessed by the ROC curve analysis using random 542 
controls as a comparison group and this analysis was repeated for each SGA phenotype. Group 543 
means of DLK1 were compared using independent two-sample t tests between SGA cases and 544 
random controls. Paired t tests were used to compare SGA cases and their matched controls. Power 545 
analyses were performed for both types of tests. Sample size calculation demonstrated that the 546 
paired analyses were well powered. We had 90% power to detect a 7.3 ng/mL within-pair difference 547 
in DLK1 measurements (n=43 pairs), assuming the observed standard deviation of the difference 548 
(14.5 ng/mL) and alpha=0.05 (two sided). The power to detect the observed difference of 9.44 549 
ng/mL was 98.6%. For the analysis of the different phenotypes of FGR we attained 80% power to 550 
detect a difference of a 9.6 ng/mL, assuming the average observed standard deviation of the 551 
difference within the extreme decile (9.6 ng/mL), n=10 pairs and alpha=0.05. In our unpaired overall 552 
analysis, we had 80% power to detect a 7.8 ng/mL difference in DLK1 between the groups (sample 553 
sizes 45 and 41), assuming the observed combined standard deviation of the measurement (12.7 554 
ng/mL) and alpha=0.05. All analyses were performed using Stata 14.1 (StataCorp, College Station, TX, 555 
USA). 556 
 557 
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Supplementary Figure 1 
Altered body composition in Null females can be detected during embryogenesis. 
(a) Total bodyweight of virgin females at 12 weeks does not differ between genotypes. Null females have larger abdominal WAT 
deposits (b) and reduced muscle (combined gastrocnemius/soleus) (c) than WT and Mat females at 12 weeks. WT and Null n = 8, Mat 
n = 7, compared by One-way ANOVA, with Bonferroni's Multiple comparison post-hoc test with WT vs Null and WT vs Mat, *p<0.05. 
Body weight (d), crown rump (C-R) length (e) and tissue weights (f) in embryos at E18.5. Null embryos have reduced mass and length,
and reduced lean (hindlimb and forelimb) mass than embryos expressing Dlk1, WT n > 21, Null n > 13, Mat n > 10, compared by 
Kruskall-Wallace test with Dunn's Multiple comparison post-hoc test comparing WT vs Null and WT vs Mat, *p<0.05, ***p<0.001. (g) 
Null mice are born small but catch up in the preweaning period. Serial measurements of pup weight from birth to weaning, Nulls weigh 
significantly less at birth but not thereafter, n = 4-11 per genotype, each time point compared as above. 
 
 
Supplementary Figure 2 
Summary of experimental crosses  
Experimental crosses used to determine which compartment of the conceptus (embryo, placental fetal endothelium or placental
trophoblast) is the source of maternal circulating DLK1 in pregnancy.. 
 
 
 
Supplementary Figure 3 
Levels of pituitary Gh mRNA do not differ between the groups. 
Expression levels of Gh (a) measured by real-time quantitative PCR in pituitaries from females in the cohort. Gh levels did not differ 
between the groups. Data was normalised to β-actin levels, then expressed as WT = 1. Groups were compared by One-way ANOVA, 
with Bonferroni's Multiple comparison post-hoc test with WT vs Null and WT x WT vs Null x WT and Null x Null, ***p<0.001. 
Supplementary Material 
Supplementary Tables 
Cross  Litter parameters, E15.5 
(Maternal x 
paternal)   
Maternal 
plasma 
DLK1 
(ng/ml) 
№ live 
conceptuses 
№ 
resorptions 
№ 
expressing 
Dlk1 
Maternal 
plasma DLK1 
(ng/ml/expr. 
conceptus) 
Total 
litter 
mass 
(g) 
WT x WT 
Mean 223 7.3 0.4 7.3 32.4 3.9 
S.e.m 24 0.4 0.3 0.4 4.4 0.2 
n = 8 
Null x WT 
Mean 275 8.4 1.1 8.4 33.1 4.5 
S.e.m 27 0.5 0.4 0.5 2.6 0.3 
n = 8 
Null x Mat 
Mean 178 8.5 0.3 3.9 45.8 4.5 
S.e.m 17 0.2 0.2 0.3 2.8 0.1 
n = 8 
Null x Null 
Mean absent 8.8 0.4 0 n/a 4.3 
S.e.m   0.3 0.3     0.2 
n = 8 
Mat x WT 
Mean 270 7.1 0.6 7.1 38.4 3.6 
S.e.m 18 0.5 0.2 0.5 2.2 0.3 
n = 8 
Mat x Null 
Mean 49 7.6 0.5 0 n/a 3.9 
S.e.m 5 0.3 0.3     0.2 
n = 8 
Null x Null-
TG 
Mean 240 8.4 0.6 5.0 46.9 
S.e.m 33 0.2 0.1 0.2 1.6 
n = 6 
Meox2Cre+/- 
x WT 
Mean 268.6 9.2 0.7 9.2 30.4 
S.e.m 23 0.5 0.3 0.5 3.4 
n = 6 
Meox2Cre+/-
x Dlk1
fl/fl 
Mean 180 8.4 0.5 4.5 42.6 
S.e.m 28 0.7 0.3 0.6 7.8 
n = 6 
Suppl Table 1. Litter parameters following intercrosses of Dlk1-expressing (WT and Mat) and non-
expressing (Null) mice, and crosses to discover the source of maternal circulating DLK1 (Null x Null-TG and 
Meox2Cre+/-x Dlk1
fl/fl
). Mean and standard error of the mean (s.e.m) is shown for n = 6-8 litters per cross. 
№ expressing conceptuses is generated by genotyping litters; based on its imprinting status WT and Mat 
offspring are counted as expressing Dlk1 and Pat and Nulls as non-expressing. Total litter mass is the sum 
of all placental and embryonic masses within the litter. 
Cross  Body Weight Gain and Food Intake (g) 
(Maternal 
x 
paternal) 
  Weight at E0.5 
Weight 
at E7.5 
Weight 
at 
E15.5 
Gain 
E0.5 to 
E7.5 
Gain 
E7.5 to 
E15.5 
Food 
consumed 
E0.5 to 
E7.5 
Food 
consumed 
E7.5 to 
E15.5 
WT NP 
Mean 21.0 21.6 22.4 0.8 0.8 31.0 30.7 
s.e.m 0.3 0.3 0.2 0.2 0.4 0.7 1.1 
n  8 
WT x WT 
Mean 19.7 21.9 30.5 2.7 8.6 29.1 33.4 
s.e.m 0.7 0.6 0.9 0.2 0.4 1.0 1.3 
n  8 
Null NP 
Mean 19.8 21.1 21.6 1.5 0.5 28.8 29.8 
s.e.m 0.3 0.4 0.4 0.2 0.4 1.4 0.9 
n  8 
Null x WT 
Mean 21.7 23.9 32.9 2.8 9.0 28.9 33.6 
s.e.m 0.4 0.4 0.7 0.3 0.5 1.0 1.0 
n  8 
Null x Mat 
Mean 20.8 22.9 31.9 2.5 9.0 28.1 32.3 
s.e.m 0.4 0.5 0.7 0.1 0.3 1.0 1.6 
n  8 
Null x Null 
Mean 21.4 23.9 32.4 2.5 8.5 28.2 32.5 
s.e.m 0.8 0.9 0.8 0.3 0.3 1.2 1.0 
n  8 
Mat NP 
Mean 20.7 21.7 21.7 1.0 0.0 30.6 29.0 
s.e.m 0.4 0.6 0.5 0.3 0.1 1.3 0.7 
n  7 
Mat x WT 
Mean 18.4 20.6 29.0 2.4 8.4 27.4 31.2 
s.e.m 0.6 0.7 1.0 0.3 0.4 1.0 1.3 
n  8 
Mat x Null 
Mean 20.1 22.2 31.0 2.6 8.7 28.0 33.2 
s.e.m 0.6 0.7 0.8 0.3 0.4 1.1 0.8 
n  8 
Suppl. Table 2. Maternal body weight and food intake parameters following intercrosses of Dlk1-
expressing (WT and Mat) and non-expressing (Null) mice. Mean and standard error of the mean 
(s.e.m) is shown for n = 7-8 litters per cross. No difference in body weight gain or food intake were 
observed between maternal genotypes/crosses.  
  
Cross  Maternal tissue mass, E15.5 (g) 
(Maternal x 
paternal)   Liver 
Abd. 
WAT 
(L+R 
depots) 
Retrop. 
WAT 
(L+R 
depots) 
Intersc. 
BAT (L+R 
depots) 
GC+SL 
muscle 
(R) 
Brain 
WT NP 
Mean 1.08 0.18a, d 0.032a 0.067a 0.123 0.489 
s.e.m. 0.04 0.01 0.002 0.006 0.004 0.004 
n 8 8 8 8 8 8 
WT x WT 
Mean 1.55 0.27a 0.061a 0.126a 0.122 0.481 
s.e.m. 0.06 0.02 0.005 0.011 0.006 0.01 
n 8 8 8 8 8 8 
Null NP 
Mean 1.06 0.28b, d 0.034b 0.059b 0.107 0.487 
s.e.m. 0.04 0.04 0.003 0.005 0.003 0.006 
n 8 8 8 8 7 7 
Null x WT 
Mean 1.70 0.33b 0.060b 0.102b 0.116 0.477 
s.e.m. 0.06 0.02 0.005 0.007 0.003 0.007 
n 8 8 8 8 6 8 
Null x Mat 
Mean 1.70 0.36 0.057 0.100 0.107 0.473 
s.e.m. 0.07 0.03 0.004 0.004 0.002 0.003 
n 8 8 8 8 7 8 
Null x Null 
Mean 1.73 0.35 0.051 0.115 0.115 0.484 
s.e.m. 0.07 0.04 0.008 0.009 0.003 0.004 
n 8 8 8 8 6 8 
Mat NP 
Mean 1.10 0.17c 0.024c 0.066c 0.121 0.474 
s.e.m. 0.04 0.02 0.003 0.005 0.003 0.008 
n 7 7 7 7 6 7 
Mat x WT 
Mean 1.64 0.26c 0.057c 0.116c 0.109 0.459 
s.e.m. 0.05 0.02 0.004 0.005 0.006 0.008 
n 8 8 8 8 7 8 
Mat x Null 
Mean 1.62 0.28 0.060 0.112 0.129 0.485 
s.e.m. 0.08 0.03 0.005 0.009 0.002 0.005 
n 8 8 8 8 7 8 
Suppl Table 3. Organ weights in age-matched virgins and pregnant mice at E15.5. Organs dissected 
were intra-abdominal WAT (including both gonadal and renal deposits, Abd WAT); retroperitoneal 
WAT (Retrop. WAT); Interscapular BAT (Intersc. BAT); hindlimb muscle (gastrocnemius (GC) and 
soleus (SL) combined) and the brain. For the adipose tissue both left (L) and right (R) depot weights 
were combined. Groups (except BAT) were compared by One-way ANOVA with Bonferroni’s post-
hoc tests as indicated: WT NP vs WT x WTa; Null NP vs Null x WTb; Mat NP vs Mat x WTc; NP WT x NP 
Nulld; Abd WAT, retrop. WAT, and liver weight increased with pregnancy for all 3 maternal 
genotypes. Non-pregnant Null abdominal WAT was heavier than non-pregnant WT Abd-WATd. BAT 
weight increased with pregnancy for all 3 maternal genotypes, compared by Kruskall-Wallace test 
with Dunn’s post-hoc test (WT NP vs WT x WTa; Null NP vs Null x WTb; Mat NP vs Mat x WTc; NP WT x 
NP Nulld). All post-hoc tests(a-d) p < 0.05.  
Cross  
 
Free-fed serum metabolites, E15.5 
 
(Maternal x 
paternal)   
Glucose 
(mmol/l) 
Insulin 
(ng/ml) 
Total 
cholesterol 
(mmol/l) 
HDL 
cholesterol 
(mmol/l) 
LDL 
cholesterol 
(mmol/l) 
TAG 
(mg/ml) 
NEFAs 
(μmol/l) 
3'OH 
butyrate 
(μmol/l) 
WT NP  
(n = 8) 
Mean 7.6 0.25 1.84 0.87 0.76 0.40 233 368 
s.e.m. 0.3 0.04 0.10 0.06 0.04 0.03 40 48 
 
              
 
WT x WT 
(n = 8) 
Mean 7.0 0.42 1.58 0.52 0.64 0.81 173 401 
s.e.m. 0.5 0.04 0.08 0.04 0.05 0.10 50 68 
 
              
 
Null NP 
(n = 8) 
Mean 7.2 0.35 2.00 0.89 0.91 0.39 185 396 
s.e.m. 0.4 0.06 0.10 0.04 0.07 0.02 36 49 
 
              
 
Null x WT 
(n = 8) 
Mean 7.3 0.49 1.64 0.48a 0.71 0.81 148 424 
s.e.m. 0.3 0.12 0.05 0.02 0.06 0.10 17 83 
 
              
 
Null x Null 
(n = 8) 
Mean 7.0 0.44 1.80 0.60a 0.73 0.92 152 414 
s.e.m. 0.3 0.15 0.06 0.02 0.05 0.06 11 29 
 
    
 
       
 
Mat NP 
(n = 7) 
Mean 7.8 0.25 1.71 0.77 0.72 0.42 237 429 
s.e.m. 0.3 0.03 0.08 0.06 0.03 0.04 43 58 
 
              
 
Mat x WT 
(n = 8) 
Mean 6.9 0.44 1.58 0.54 0.52 0.99 218 475b 
s.e.m. 0.5 0.06 0.11 0.05 0.08 0.12 17 38 
 
              
 
Mat x Null 
(n = 8) 
Mean 6.8 0.43 1.60 0.56 0.64 0.79 157 340b 
se.m. 0.2 0.04 0.08 0.03 0.09 0.11 26 58 
 
              
 Suppl Table 4. Maternal metabolites in free-fed plasma at E15.5.  
All groups were compared by One-way ANOVA with Bonferroni’s post-hoc tests as indicated:  Null x 
WT vs Null x Nulla, Mat x WT vs Mat x Nullb. All post-hoc tests(a-b) p < 0.05. 
  
Cross    Conceptus genotype 
(Maternal x 
paternal)   WT Mat Pat Null 
All crosses 
Embryo mean (mg) 431 445 418 405 
S.e.m. 9 9 9 7 
Placenta mean (mg) 101 100 98 92 
S.e.m. 3 2 3 2 
n (litters) 16 24 8 24 
n (conceptuses) 94 96 32 166 
WT x WT (n = 8 
litters) 
Embryo mean (mg) 438       
S.e.m. 11    
Placenta mean (mg) 107 
  
  
S.e.m 6 
  
  
Null x WT (n = 8 
litters) 
Embryo mean (mg)   442     
S.e.m. 
 
15 
 
  
Placenta mean (mg) 
 
100 
 
  
S.e.m. 
 
4 
 
  
Null x Mat (n = 8 
litters) 
Embryo mean (mg)   471   404 
S.e.m. 
 
12 
 
9 
Placenta mean (mg) 
 
100 
 
88 
S.e.m. 
 
1 
 
2 
Null x Null (n = 8 
litters) 
Embryo mean (mg)       402 
S.e.m. 
   
16 
Placenta mean (mg) 
   
90 
S.e.m. 
   
1 
Mat x WT (n = 8 
litters) 
Embryo mean (mg) 424 420     
S.e.m. 15 14 
 
  
Placenta mean (mg) 95 98 
 
  
S.e.m. 2 3 
 
  
Mat x Null (n = 8 
litters) 
Embryo mean (mg)     418 410 
S.e.m. 
  
9 9 
Placenta mean (mg) 
  
98 99 
S.e.m.     3 4 
Suppl Table 5. Wet weights of embryos and placentas from each cross at E15.5, by conceptus 
genotype.  A grey box indicates that the embryo genotype is not generated by that particular cross. 
Mat embryos in Null x Mat litters (bold) are significantly heavier than other Mat embryos (Null x WT: 
443 ± 6 mg, n = 67; Null x Mat: 471 ± 7, n = 29; Mat x WT = 420 ± 8, n = 30; One-way ANOVA p = 
0.0003, Bonferroni’s Multiple comparison test Null x WT vs Null x Mat, p < 0.05; Mat x WT vs Null x 
Mat, p < 0.001).  
  
Characteristic  
 
Case (SGA-cust<5th) 
(n=45) 
Matched control 
(n=43) 
Unmatched control 
(n=41) 
    
Maternal characteristics    
Age, years 31 (27 to 34) 31 (28 to 34) 31 (26 to 35) 
     
Age stopped FTE, years 18 (16 to 23) 21 (19 to 23) 21 (18 to 23) 
 Missing 
 
0 (0.0) 1 (2.3) 0 (0.0) 
Height, cm 165 (160 to 170) 167 (160 to 172) 164 (161 to 169) 
     
Deprivation quartile    
 1 (lowest) 14 (31) 11 (26) 11 (27) 
 2 7 (16) 11 (26) 10 (24) 
 3 11 (24) 8 (19) 6 (15) 
 4 (highest) 9 (20) 11 (26) 10 (24) 
 Missing  
 
4 (8.9) 2 (4.7) 4 (9.8) 
Ethnicity    
 Non-white  2 (4.4) 4 (9.3) 4 (9.8) 
 White 42 (93) 39 (91) 37 (90) 
 Missing  
 
1 (2.2) 0 (0.0) 0 (0.0) 
Married 22 (49) 26 (60) 28 (68) 
     
Smoker 4 (8.9) 1 (2.3) 1 (2.4) 
     
Any alcohol consumption 2 (4.4) 1 (2.3) 1 (2.4) 
     
BMI, kg/m2 25 (23 to 30) 25 (22 to 28) 24 (22 to 28) 
     
Gestational age at 36 week blood 
sampling, days 
253 (252 to 255) 254 (252 to 254) 253 (252 to 254) 
     
Birth outcomes    
     
Gestational age, weeks 40.7 (39.3 to 41.3) 40.6 (39.4 to 41.1) 40.4 (39.3 to 41.6) 
     
Induction of labour 13 (29) 8 (19) 15 (37) 
     
Mode of delivery    
 Spontaneous vaginal 19 (42) 21 (49) 13 (32)  
 Operative vaginal 10 (22) 6 (14) 15 (37) 
 Pre-labour caesarean 7 (16) 8 (19) 3 (7.3) 
 Intrapartum caesarean 9 (20) 8 (19) 10 (24) 
     
DLK1 (ng/mL) 34 (28 to 43) 44 (36 to 53) 41 (33 to 54) 
    
Suppl Table 6. Characteristics of the study cohort, by case-control status. Data are expressed as 
median (IQR) or n (%) as appropriate. For fields where there is no category labelled "missing", data 
were 100% complete. Case group consist of 43 matched cases and 2 women who were originally 
part of the unmatched control group and were re-labelled as cases (SGA-cust<5th).  
  
Matching characteristic  
 
Difference:  
case - control 
(n=43 pairs) 
  
Gestational age at 36 week blood 
sampling, days 
0 (-1 to 2) 
   
Smoking at booking  
 No difference 40 (93) 
 Case: smoker, control: non-
smoker 
2 (4.7) 
 Case: non-smoker, control: 
smoker 
1 (2.3) 
   
BMI, kg/m2 1.8 (-1.6 to 4.0) 
   
Maternal age, years -1.1 (-2.7 to 3.2) 
   
Mode of delivery  
 No difference 41 (95) 
 Case: intrapartum caesarean, 
control: vaginal 
1 (2.3) 
 Case: vaginal, control: pre-
labour caesarean 
1 (2.3) 
  
Fetal sex  
 No difference 42 (98) 
 Case: female, control: male 1 (2.3) 
   
Suppl Table 7. Difference in the matching characteristics between cases and controls, paired analysis 
Data are expressed as median (IQR) or n (%) as appropriate.  
Birth outcomes 
 
FGR 
(n=23) 
Healthy SGA 
(n=20) 
P value 
    
Gestational age, weeks 40.3 (38.9 to 41.6) 40.8 (40.1 to 41.2) 0.35 
     
Birth weight, g 2640 (2370 to 2880) 2848 (2700 to 2920) 0.047 
Birth weight percentile 1 (1 to 3) 3 (2 to 4) 0.022 
     
ACGV percentile 8.9 (2.2 to 53.0) 28.2 (12.9 to 45.9) 0.12 
     
Induction of labour 9 (39) 4 (20) 0.20 
     
Mode of delivery    
 Spontaneous vaginal 12 (52) 5 (25)  
0.086  Operative vaginal 3 (13) 7 (35) 
 Pre-labour caesarean 5 (22) 2 (10) 
 Intrapartum caesarean 3 (13) 6 (30)  
     
Preeclampsia 2 (8.7) 0 (0.0) 0.49 
     
Any neonatal morbidity 6 (26) 4 (20) 0.73 
     
Suppl Table 8. Comparison of birth outcomes between SGA infants with and without any indication 
of FGR in the POP study. Data are expressed as median (IQR) or n (%) as appropriate. All 43 SGA 
infants were liveborn at term. Spearman correlation coefficient between DLK1 difference from the 
matched control and birth weight percentile was 0.41. P values are for differences between groups, 
calculated using the two-sample Wilcoxon rank-sum (Mann-Whitney) test for continuous variables 
and the Pearson Chi-square test or Fisher’s exact test for categorical variables. Abbreviations: ACGV 
= abdominal circumference growth velocity and FGR = fetal growth restriction. 
  
 Comparison  
 
Test Difference 
(mean) 
P value 
    
All cases (n=45)  
vs. unmatched controls (n=41) 
Unpaired t test, equal variances -6.93 0.011 
     
    
Matched cases vs. matched 
controls (n=43 pairs) 
Paired t test, difference ≠ 0 -9.44 0.0001 
     
UTPI 20wkGA    
 Highest decile (n=8 pairs) Paired t test, difference ≠ 0 -7.64 0.094 
 Deciles 1-9 (n=32 pairs) Paired t test, difference ≠ 0 -10.49 0.0002           
 Highest decile vs. deciles 1-9 Paired t test, equal variances 2.85  0.59 
     
UMPI 36wkGA    
 Highest decile (n=10 pairs) Paired t test, difference ≠ 0 -17.13 <0.0001 
 Deciles 1-9 (n=33 pairs) Paired t test, difference ≠ 0 -7.11 0.014           
 Highest decile vs. deciles 1-9 Paired t test, unequal variances* -10.02 0.0029 
     
ACGV 20-36wkGA    
 Lowest decile (n=12 pairs) Paired t test, difference ≠ 0 -11.96 0.0070 
 Deciles 2-10 (n=31 pairs) Paired t test, difference ≠ 0 -8.47 0.0044  
 Lowest decile vs. deciles 2-10 Paired t test, equal variances -3.49 0.49 
     
Any FGR indicator    
 Yes (n=23 pairs) Paired t test, difference ≠ 0 -13.33 <0.0001 
 No (n=20 pairs) Paired t test, difference ≠ 0 -4.97 0.22 
 Yes vs. No Paired t test, unequal variances* -8.36 0.070 
    
Suppl Table 9. Comparison of DLK1 between cases and controls. *Result from variance ratio test for 
the equality of variances between the groups: p<0.05. Abbreviations: UTPI = uterine artery Doppler 
Pulsatility Index, UMPI = umbilical artery Doppler Pulsatility Index, ACGV = abdominal circumference 
growth velocity, FGR = fetal growth restriction. 
  
Gene Primer sequence (forward) Primer sequence (reverse) Reference 
α-tubulin AGACCATTGGGGGAGGAGAT GTGGGTTCCAGGTCTACGAA 
Charalambous M et 
al., 2012. Hprt CAGGCCAGACTTTGTTGGAT TTGCGCTCATCTTAGGCTTT 
Dlk1 GAAAGGACTGCCAGCACAAG CACAGAAGTTGCCTGAGAAGC 
Hmgcs2 TGGTGGATGGGAAGCTGTCT GAGGGTGAAAGGCTGGTTGTT 
Lambert G et al., 
2006 
actin TTCTTTGCAGCTCCTTCGTT ATGGAGGGGAATACAGCCC Dorrell C et al., 2011 
Gh 
TGGGCAGATCCTCAAGCAAACCTA GAAGGCACAGCTGCTTTCCACAAA Barclay et. al., 2006 
 
 
Suppl Table 10. Real-time qPCR primers used in the study. 
  
Characteristic  
 
SGA in analysis 
(n=45) 
SGA not in analysis 
(n=178) 
P value 
    
Maternal characteristics    
     
Age, years 31 (27 to 34) 30 (25 to 34) 0.38 
     
Age stopped FTE, years 18 (16 to 23) 20 (18 to 23) 0.47 
 Missing 
 
0 (0.0) 5 (2.8)  
Height, cm 165 (160 to 170) 165 (160 to 168) 0.31 
     
Deprivation quartile    
 1 (lowest) 14 (31) 39 (22)  
0.13  2 7 (16) 30 (17) 
 3 11 (24) 47 (26) 
 4 (highest) 9 (20) 53 (30) 
 Missing  
 
4 (8.9) 9 (5.1)  
Ethnicity    
 Non-white  2 (4.4) 9 (5.1) 0.88 
 White 42 (93) 167 (94) 
 Missing  
 
1 (2.2) 2 (1.1)  
Married 22 (49) 112 (63) 0.086 
     
Smoker 4 (8.9) 29 (16) 0.21 
     
Any alcohol consumption 2 (4.4) 6 (3.4) 0.73 
     
BMI, kg/m2 25 (23 to 30) 25 (23 to 29) 0.77 
     
Birth outcomes    
     
Gestational age, weeks 40.7 (39.3 to 41.3) 39.9 (38.1 to 41.0) 0.012 
     
Birth weight, g 2805 (2460 to 2900) 2625 (2220 to 2820) 0.0020 
Birth weight percentile 3 (1 to 3) 2 (1 to 3) 0.052 
     
Induction of labour 13 (29) 60 (34) 0.54 
     
Mode of delivery    
 Spontaneous vaginal 19 (42) 90 (51)  
0.30  Operative vaginal 10 (22) 33 (19) 
 Pre-labour caesarean 7 (16) 19 (11) 
 Intrapartum caesarean 9 (20) 36 (20) 
     
Suppl Table 11. Comparison of SGA infants included in the analysis and all other SGA infants in the 
POP study Data are expressed as median (IQR) or n (%) as appropriate. For fields without a category 
labelled "missing", data were 100% complete. P values are for differences between groups, 
calculated using the two-sample Wilcoxon rank-sum (Mann-Whitney) test for continuous variables 
and the Pearson Chi-square test for categorical variables, with trend tests where appropriate.
